Sun Pharmaceutical Industries announced on Tuesday that it has launched Flu Guard at a price of Rs. 35 per tablet, for treating mild to moderate cases of coronavirus infection in India.

Flu Guard (Favipiravir 200mg) is the only oral anti-viral treatment approved in India by the DGCI for the potential treatment of patients with mild to moderate COVID-19 disease, the pharma company said. Favipiravir and Remdesivir have turned out to be the most sought after medicines to treat COVID-19 in India.

CEO of India Business of Sun Pharma, Kirti Ganorkar, said, "With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India's pandemic response".